APTX stock forecast
Our latest prediction for Aptinyx, Inc.'s stock price was made on the Jan. 14, 2020 when the stock price was at 3.24$.
In the short term (2weeks), APTX's stock price should outperform the market by 2.07%. During that period the price should oscillate between -10.14% and +16.73%.
In the medium term (3months), APTX's stock price should underperform the market by -9.37%. During that period the price should oscillate between -42.86% and +42.05%.Get email alerts
About Aptinyx, Inc.
Aptinyx Inc. is a clinical stage biopharmaceutical company. It engages in the discovery, development, and and commercialization of transformative therapies for disorders of the brain and nervous system. Its product includes NYX-2925, NYX-783, NYX-458, and the AGN-241751 program. The company was founded by Norbert G. Riedel and Joseph R. Moskal in June 2015 and is headquartered in Evanston, IL.
At the moment the company generates 4M USD in revenues.
On its last earning announcement, the company reported a loss of -1.46$ per share.
The book value per share is 5.24$
Three months stock forecastJan. 14, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|